AmMax
AmMax Bio is a clinical-stage biotechnology company focused on developing innovative therapeutics for cancer patients. Founded in 2020 by Larry Hsu, Ph.D., the company leverages its CSF1R-targeting platform to address significant unmet needs in oncology. Its pipeline includes first-in-class treatments such as AMB-066 for colorectal cancer with minimal residual disease (CRC MRD), AMB-104 for acute myeloid leukemia (AML), and AMB-051 for tenosynovial giant cell tumor (TGCT). The company aims to bring practice-changing medicines to patients with cancer.
Industries
Nr. of Employees
small (1-50)
AmMax
Redwood City, California, United States
Patents
Targeted delivery of anti-CSF1R antibodies to joints with tenosynovial giant cell tumors
US-11752096-B2
View Details
Targeted delivery of anti-CSF1R antibodies to joints with tenosynovial giant cell tumors
US-11752096-B2
View DetailsProducts
Clinical-stage CSF1R-targeting monoclonal antibody for colorectal cancer MRD
A CSF1R-targeting monoclonal antibody developed to deplete pro-tumorigenic macrophages and alter the tumor microenvironment; evaluated in a Phase 2a study for colorectal cancer patients with minimal residual disease using ctDNA-informed endpoints.
Pre-IND CSF1R-targeting antibody-drug conjugate for AML
An antibody-drug conjugate that uses a CSF1R-targeting antibody linked to a clinically validated cytotoxic payload (exatecan-class) developed for acute myeloid leukemia and select solid tumors; supported by target overexpression and internalization data.
Locally administered CSF1R-targeting injection for tenosynovial giant cell tumor (TGCT)
A locally administered intra-articular biologic candidate developed for treatment of tenosynovial giant cell tumor (TGCT), leveraging local delivery to the disease site.
AMB 051
Monoclonal antibody program targeting tenosynovial giant cell tumor (TGCT).
AMB 104
An antibody-drug conjugate (ADC) program targeting acute myeloid leukemia (AML).
AMB 066
Monoclonal antibody program targeting colorectal cancer with minimal residual disease (CRC MRD).
Clinical-stage CSF1R-targeting monoclonal antibody for colorectal cancer MRD
A CSF1R-targeting monoclonal antibody developed to deplete pro-tumorigenic macrophages and alter the tumor microenvironment; evaluated in a Phase 2a study for colorectal cancer patients with minimal residual disease using ctDNA-informed endpoints.
Pre-IND CSF1R-targeting antibody-drug conjugate for AML
An antibody-drug conjugate that uses a CSF1R-targeting antibody linked to a clinically validated cytotoxic payload (exatecan-class) developed for acute myeloid leukemia and select solid tumors; supported by target overexpression and internalization data.
Locally administered CSF1R-targeting injection for tenosynovial giant cell tumor (TGCT)
A locally administered intra-articular biologic candidate developed for treatment of tenosynovial giant cell tumor (TGCT), leveraging local delivery to the disease site.
AMB 051
Monoclonal antibody program targeting tenosynovial giant cell tumor (TGCT).
AMB 104
An antibody-drug conjugate (ADC) program targeting acute myeloid leukemia (AML).
AMB 066
Monoclonal antibody program targeting colorectal cancer with minimal residual disease (CRC MRD).
Services
Structuring and executing exclusive license agreements and clinical collaborations with academic cancer centers to advance translational discoveries into clinical trials.
Target validation, internalization and efficacy studies, and execution of IND-enabling experiments to support regulatory submissions for clinical entry.
Designing trials that use ctDNA-based patient selection and ctDNA clearance as primary endpoints to evaluate minimal residual disease therapies.
Structuring and executing exclusive license agreements and clinical collaborations with academic cancer centers to advance translational discoveries into clinical trials.
Target validation, internalization and efficacy studies, and execution of IND-enabling experiments to support regulatory submissions for clinical entry.
Designing trials that use ctDNA-based patient selection and ctDNA clearance as primary endpoints to evaluate minimal residual disease therapies.
Expertise Areas
- Clinical trial management (early-phase oncology)
- Biomarker-driven development (ctDNA/MRD)
- Monoclonal antibody therapeutics
- Antibody-drug conjugate development
Key Technologies
- Monoclonal antibody therapeutics
- Antibody-drug conjugates (ADC)
- Circulating tumor DNA (ctDNA) assays
- In vitro and in vivo preclinical models
News & Updates
AmMax Bio will present at the 2025 BIO-Europe Spring Convention in Milan, Italy, on March 18, 2025.
AmMax announced the dosing of the first patient in its Phase 2a study evaluating AMB-066 for CRC MRD at MD Anderson Cancer Center.
AmMax and MD Anderson announced agreements to develop and evaluate AMB-066 for CRC MRD.
AmMax Bio will present at the 2025 BIO-Europe Spring Convention in Milan, Italy, on March 18, 2025.
AmMax announced the dosing of the first patient in its Phase 2a study evaluating AMB-066 for CRC MRD at MD Anderson Cancer Center.
AmMax and MD Anderson announced agreements to develop and evaluate AMB-066 for CRC MRD.